Terran Biosciences Entered into an Exclusive License Agreement with Pierre Fabre for Idazoxan to Treat Schizophrenia
- Terran to get exclusive development and commercialization rights globally for idazoxan (selective alpha 2 receptor antagonist) for schizophrenia
- The P-II proof-of-concept trials results showed the safety and efficacy of idazoxan as adjunctive therapy, improvement in symptoms double that of standard antipsychotic therapy alone & showed a short half-life, requiring 3 daily doses to achieve the desired plasma levels and pharmacological effects
- The first cohort of study participants has received their doses, and early analysis showed that the qd pharmacokinetic profile was effectively attained while the development of novel XR formulation and GMP manufacturing completed to P-III standards
Ref: PR Newswire | Image: Terran Biosciences
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at firstname.lastname@example.org
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.